JP2005524663A - 神経エントラップメント症候群の処置方法 - Google Patents
神経エントラップメント症候群の処置方法 Download PDFInfo
- Publication number
- JP2005524663A JP2005524663A JP2003572516A JP2003572516A JP2005524663A JP 2005524663 A JP2005524663 A JP 2005524663A JP 2003572516 A JP2003572516 A JP 2003572516A JP 2003572516 A JP2003572516 A JP 2003572516A JP 2005524663 A JP2005524663 A JP 2005524663A
- Authority
- JP
- Japan
- Prior art keywords
- syndrome
- nerve
- pain
- botulinum toxin
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 18
- 208000019382 nerve compression syndrome Diseases 0.000 title claims abstract description 9
- 238000011282 treatment Methods 0.000 title claims description 19
- 208000002193 Pain Diseases 0.000 claims abstract description 32
- 230000036407 pain Effects 0.000 claims abstract description 30
- 210000005036 nerve Anatomy 0.000 claims abstract description 17
- 108010074523 rimabotulinumtoxinB Proteins 0.000 claims abstract description 15
- 210000002808 connective tissue Anatomy 0.000 claims abstract description 4
- 210000003205 muscle Anatomy 0.000 claims description 17
- 230000006835 compression Effects 0.000 claims description 13
- 238000007906 compression Methods 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 231100000765 toxin Toxicity 0.000 claims description 9
- 239000003053 toxin Substances 0.000 claims description 9
- 208000008713 Piriformis Muscle Syndrome Diseases 0.000 claims description 4
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 4
- 206010049433 piriformis syndrome Diseases 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 description 13
- 108030001720 Bontoxilysin Proteins 0.000 description 9
- 210000000707 wrist Anatomy 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 8
- 229940053031 botulinum toxin Drugs 0.000 description 7
- 210000003497 sciatic nerve Anatomy 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 210000003811 finger Anatomy 0.000 description 6
- 208000034783 hypoesthesia Diseases 0.000 description 6
- 231100000862 numbness Toxicity 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 206010033799 Paralysis Diseases 0.000 description 5
- 210000002414 leg Anatomy 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 229940112646 myobloc Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000003813 thumb Anatomy 0.000 description 5
- 206010029174 Nerve compression Diseases 0.000 description 4
- 206010040021 Sensory abnormalities Diseases 0.000 description 4
- 208000030193 Tinel sign Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000001217 buttock Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 210000001617 median nerve Anatomy 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 210000000623 ulna Anatomy 0.000 description 4
- 208000008765 Sciatica Diseases 0.000 description 3
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007830 nerve conduction Effects 0.000 description 3
- 210000000578 peripheral nerve Anatomy 0.000 description 3
- 210000002979 radial nerve Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 2
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010033425 Pain in extremity Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940094657 botulinum toxin type a Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 210000000658 ulnar nerve Anatomy 0.000 description 2
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- 208000018137 Extraocular muscle disease Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 208000002240 Tennis Elbow Diseases 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 208000008593 Ulnar Nerve Compression Syndromes Diseases 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000024764 elbow pain Diseases 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000018197 inherited torticollis Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004932 little finger Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000009873 radial neuropathy Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000003270 subclavian artery Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36062802P | 2002-03-01 | 2002-03-01 | |
| PCT/US2003/006233 WO2003073994A2 (en) | 2002-03-01 | 2003-02-27 | Methods of treating nerve entrapment syndromes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005524663A true JP2005524663A (ja) | 2005-08-18 |
| JP2005524663A5 JP2005524663A5 (enExample) | 2006-04-13 |
Family
ID=27788996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003572516A Pending JP2005524663A (ja) | 2002-03-01 | 2003-02-27 | 神経エントラップメント症候群の処置方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20030224019A1 (enExample) |
| EP (1) | EP1487481A4 (enExample) |
| JP (1) | JP2005524663A (enExample) |
| KR (1) | KR20040094756A (enExample) |
| AU (2) | AU2003212473A1 (enExample) |
| CA (1) | CA2477808A1 (enExample) |
| WO (1) | WO2003073994A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7838008B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| KR20040094756A (ko) * | 2002-03-01 | 2004-11-10 | 엘란 파마슈티칼스, 인크. | 신경 포착 증후군의 치료 방법 |
| US7300412B2 (en) * | 2002-05-10 | 2007-11-27 | Hospital For Joint Diseases | Methods for therapeutic treatment of carpal tunnel syndrome |
| US8734810B2 (en) * | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
| US8871224B2 (en) | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
| US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
| US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
| US20050191321A1 (en) | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
| US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
| US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
| KR100668570B1 (ko) * | 2004-06-28 | 2007-01-16 | 입센 리미티드 | 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물 |
| US6991789B2 (en) * | 2004-06-29 | 2006-01-31 | Allergas, Inc. | Methods of modulating intracellular degradation rates of toxins |
| US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
| US7179474B2 (en) * | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
| US7429386B2 (en) * | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
| US7897147B2 (en) | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
| US7749515B2 (en) | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
| US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
| US7419675B2 (en) * | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
| US7824694B2 (en) * | 2006-01-12 | 2010-11-02 | Allergan, Inc. | Methods for enhancing therapeutic effects of a neurotoxin |
| US20070178121A1 (en) * | 2006-01-27 | 2007-08-02 | Allergan, Inc. | Methods for enhancing skin treatments |
| CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
| US9061025B2 (en) * | 2006-08-31 | 2015-06-23 | Allergan, Inc. | Methods for selecting headache patients responsive to botulinum toxin therapy |
| US8617571B2 (en) | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
| US20100028385A1 (en) * | 2008-08-04 | 2010-02-04 | Allergan, Inc. | Treatment of excess cerumen secretion |
| WO2011038015A1 (en) | 2009-09-24 | 2011-03-31 | Allergan, Inc. | Method of treating osteoporosis with a neurotoxin |
| WO2011123165A1 (en) | 2010-03-31 | 2011-10-06 | Toray Plastics (America), Inc. | Biaxially oriented polyactic acid film with reduced noise level |
| US9101794B2 (en) | 2010-09-19 | 2015-08-11 | Thomas Alan Ferguson, JR. | Piri-stretcher |
| US9782617B2 (en) | 2010-09-19 | 2017-10-10 | Thomas Alan Ferguson, JR. | Piri-stretcher system |
| USD703824S1 (en) | 2010-09-19 | 2014-04-29 | Thomas Alan Ferguson, JR. | Leg stretching device |
| US8697090B2 (en) | 2011-05-05 | 2014-04-15 | Allergan, Inc. | Method of treating persistent genital arousal disorder with a neurotoxin |
| EP2649984A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis |
| EP2836193B1 (en) | 2012-04-13 | 2018-01-31 | Lubrizol Advanced Materials, Inc. | Compounds which inhibit neuronal exocytosis (ii) |
| EP2649983A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (II) |
| EP2649985A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (III) |
| WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
| EP3470054B1 (en) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
| US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
| US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
| US10561715B2 (en) * | 2018-02-26 | 2020-02-18 | Philip Andrew RADOVIC | Plantar heel pain syndrome treatment |
| EP3660509B1 (en) | 2018-11-29 | 2022-03-09 | Hugel Inc. | A cell-based method for determining an activity of botulinum toxin |
| US12290301B1 (en) | 2024-08-19 | 2025-05-06 | Panacea Spine, LLC | Percutaneous surgical treatment for piriformis syndrome |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4932936A (en) * | 1988-01-29 | 1990-06-12 | Regents Of The University Of Minnesota | Method and device for pharmacological control of spasticity |
| US5053005A (en) * | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
| US5183462A (en) * | 1990-08-21 | 1993-02-02 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
| JP3510886B2 (ja) * | 1992-06-23 | 2004-03-29 | ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド | ボツリヌスｂ複合体を含有する医薬組成物 |
| US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| PT1086702E (pt) * | 1994-05-09 | 2005-08-31 | William J Binder | Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| US5562899A (en) * | 1995-02-28 | 1996-10-08 | Gerber; Allen | Medical prevention of lacerations to the vagina and perineum |
| US5721215A (en) * | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| US6063768A (en) * | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| US6113915A (en) * | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US6139845A (en) * | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US6358513B1 (en) * | 2000-02-15 | 2002-03-19 | Allergan Sales, Inc. | Method for treating Hashimoto's thyroiditis |
| CA2369810C (en) * | 2002-01-30 | 2007-08-07 | 1474791 Ontario Limited | Method of treating pain |
| KR20040094756A (ko) * | 2002-03-01 | 2004-11-10 | 엘란 파마슈티칼스, 인크. | 신경 포착 증후군의 치료 방법 |
-
2003
- 2003-02-27 KR KR10-2004-7013635A patent/KR20040094756A/ko not_active Ceased
- 2003-02-27 AU AU2003212473A patent/AU2003212473A1/en not_active Abandoned
- 2003-02-27 US US10/378,042 patent/US20030224019A1/en not_active Abandoned
- 2003-02-27 CA CA002477808A patent/CA2477808A1/en not_active Abandoned
- 2003-02-27 WO PCT/US2003/006233 patent/WO2003073994A2/en not_active Ceased
- 2003-02-27 EP EP03709413A patent/EP1487481A4/en not_active Withdrawn
- 2003-02-27 JP JP2003572516A patent/JP2005524663A/ja active Pending
-
2008
- 2008-03-26 US US12/056,096 patent/US20080171065A1/en not_active Abandoned
-
2009
- 2009-05-01 AU AU2009201770A patent/AU2009201770A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1487481A2 (en) | 2004-12-22 |
| US20080171065A1 (en) | 2008-07-17 |
| US20030224019A1 (en) | 2003-12-04 |
| KR20040094756A (ko) | 2004-11-10 |
| CA2477808A1 (en) | 2003-09-12 |
| AU2003212473A1 (en) | 2003-09-16 |
| WO2003073994A3 (en) | 2004-02-05 |
| AU2009201770A1 (en) | 2009-05-28 |
| EP1487481A4 (en) | 2005-11-23 |
| WO2003073994A2 (en) | 2003-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005524663A (ja) | 神経エントラップメント症候群の処置方法 | |
| Yelnik et al. | Drug treatments for spasticity | |
| Francisco et al. | Post-stroke spasticity | |
| Sölveborn | Radial epicondylalgia (‘tennis elbow'): treatment with stretching or forearm band. A prospective study with long‐term follow‐up including range‐of‐motion measurements | |
| Hsu et al. | Arthroscopic distension in the management of frozen shoulder | |
| JP4381477B2 (ja) | 筋膜疼痛症候群の治療方法 | |
| Lam et al. | Ultrasound and electrical stimulator-guided obturator nerve block with phenol in the treatment of hip adductor spasticity in long-term care patients: a randomized, triple blind, placebo controlled study | |
| Jozefczyk | The management of focal spasticity | |
| Hidayati et al. | Current diagnosis and management of carpal tunnel syndrome: A review | |
| West et al. | Effective management of spinal pain in one hundred seventy-seven patients evaluated for manipulation under anesthesia | |
| El-Etribi et al. | The effect of botulinum toxin type-A injection on spasticity, range of motion and gait patterns in children with spastic diplegic cerebral palsy: an Egyptian study | |
| Coroian et al. | Percutaneous needle tenotomy for the treatment of muscle and tendon contractures in adults with brain damage: results and complications | |
| Vaiman et al. | Oxycodone and dexamethasone for pain management after tonsillectomy: a placebo-controlled EMG assessed clinical trial | |
| Duchicela et al. | Pediatric nerve blocks: an evidence-based approach | |
| Tafler et al. | The function of osteopathic medicine in the treatment of adhesive capsulitis | |
| Koh et al. | Alcohol motor blocks: case series and a narrative review | |
| Cremata et al. | Manipulation under anesthesia: a report of four cases | |
| Cabahug | Managing spasticity in a pregnant woman with spinal cord injury: A review | |
| Ko et al. | Spasticity | |
| ZHANG et al. | Pestle needling at Yāoyángguān-Bāzhèn points for intractable lumbodynia after lumbar disc herniation surgery: A randomized controlled trial | |
| Bursa et al. | Large and Intermediate Joint Injections | |
| Schatz et al. | Cryoneurolysis and Quadriplegia: A Case Report on Pain and Severe Spasticity Management | |
| Kamruzzaman et al. | The Effect of Phonophoresis and Therapeutic Exercise in the Treatment of Adhesive Capsulitis | |
| Wilhelm et al. | 20 Upper Limb Spasticity With Botulinum Neurotoxin | |
| Fernando et al. | The physical and functional outcomes after ultrasound guided intramuscular botulinum toxin injections in ambulatory children with cerebral palsy attending to a multidisciplinary tertiary care center |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060224 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090428 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090724 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090731 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091027 |